A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (257 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-02-27. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: or equalequal togreater thandeathpancreatic
  Phrases that lowered it: screeningpharmacokineticsopen labeland safetyefficacy and
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 9.1% (raises risk) · Sponsor's track record
• Phase: 1/2 (raises risk) · Design
• Sponsor's past trials: 958 (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 140 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 22.4% (raises risk) · Drug's FDA history
• Number of arms: 12 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drugs with FDA adverse-event history: 10 (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 93.2% (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 35645 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma NCT04787991 · started 2021 · scored riskier than 26% of active trials completed
• Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma NCT02101021 · started 2014 · scored riskier than 61% of active trials terminated
• Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma NCT02558894 · started 2015 · scored riskier than 83% of active trials completed
• Azacitidine and Pembrolizumab in Pancreatic Cancer NCT03264404 · started 2017 · scored riskier than 86% of active trials completed
• Pancreatic Adenocarcinoma Signature Stratification for Treatment NCT04469556 · started 2020 · scored riskier than 85% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.